Genmab — Juli 2019
-
nææhh men det er og bliver det evindelige problem at pharma i sidste ende tænker mest på indtjening og ikke patienten uanset hvordan man forsøger at sælge sig selv - og med de altid stigende udgifter der er til sundhedssektoren, så var dette jo også en vej fremad.
-
Lægerne kan jo nok finde ud af det selv. DRd og VRd kommer til at dele i porten. Om det bliver fifty fifty må tiden vise. Men DRd har jo sin stærke side i dara's fornemme bivirkningsprofil. Så de svage vil fa D i stedet for V, som er langt mere giftig. Og desuden kan D komme på banen for high risk pts.
-
Iberdomide
Iberdomide | C25H27N3O5 | CID 67335295 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
(pubchem.ncbi.nlm.nih.gov)
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind